AZ505 - CAS 1035227-43-0
Catalog number: 1035227-43-0
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
AZ505 is a potent and highly selective inhibitor of the oncogenic protein SMYD2(IC50=0.12 μM) with potential anticancer activity.
AZ505; AZ 505; AZ-505
Canonical SMILES:
1.Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.
Li LX;Fan LX;Zhou JX;Grantham JJ;Calvet JP;Sage J;Li X J Clin Invest. 2017 Jun 30;127(7):2751-2764. doi: 10.1172/JCI90921. Epub 2017 Jun 12.
Autosomal dominant polycystic kidney disease (ADPKD) is driven by mutations in PKD1 and PKD2 genes. Recent work suggests that epigenetic modulation of gene expression and protein function may play a role in ADPKD pathogenesis. In this study, we identified SMYD2, a SET and MYND domain protein with lysine methyltransferase activity, as a regulator of renal cyst growth. SMYD2 was upregulated in renal epithelial cells and tissues from Pkd1-knockout mice as well as in ADPKD patients. SMYD2 deficiency delayed renal cyst growth in postnatal kidneys from Pkd1 mutant mice. Pkd1 and Smyd2 double-knockout mice lived longer than Pkd1-knockout mice. Targeting SMYD2 with its specific inhibitor, AZ505, delayed cyst growth in both early- and later-stage Pkd1 conditional knockout mouse models. SMYD2 carried out its function via methylation and activation of STAT3 and the p65 subunit of NF-κB, leading to increased cystic renal epithelial cell proliferation and survival. We further identified two positive feedback loops that integrate epigenetic regulation and renal inflammation in cyst development: SMYD2/IL-6/STAT3/SMYD2 and SMYD2/TNF-α/NF-κB/SMYD2. These pathways provide mechanisms by which SMYD2 might be induced by cyst fluid IL-6 and TNF-α in ADPKD kidneys.
2.Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
Li LX;Zhou JX;Calvet JP;Godwin AK;Jensen RA;Li X Cell Death Dis. 2018 Feb 27;9(3):326. doi: 10.1038/s41419-018-0347-x.
We identified SMYD2, a SMYD (SET and MYND domain) family protein with lysine methyltransferase activity, as a novel breast cancer oncogene. SMYD2 was expressed at significantly higher levels in breast cancer cell lines and in breast tumor tissues. Silencing of SMYD2 by RNAi in triple-negative breast cancer (TNBC) cell lines or inhibition of SMYD2 with its specific inhibitor, AZ505, significantly reduced tumor growth in vivo. SMYD2 executes this activity via methylation and activation of its novel non-histone substrates, including STAT3 and the p65 subunit of NF-κB, leading to increased TNBC cell proliferation and survival. There are cross-talk and synergistic effects among SMYD2, STAT3, and NF-κB in TNBC cells, in that STAT3 can contribute to the modification of NF-κB p65 subunit post-translationally by recruitment of SMYD2, whereas the p65 subunit of NF-κB can also contribute to the modification of STAT3 post-translationally by recruitment of SMYD2, leading to methylation and activation of STAT3 and p65 in these cells. The expression of SMYD2 can be upregulated by IL-6-STAT3 and TNFα-NF-κB signaling, which integrates epigenetic regulation to inflammation in TNBC development. In addition, we have identified a novel SMYD2 transcriptional target gene, PTPN13, which links SMYD2 to other known breast cancer associated signaling pathways, including ERK, mTOR, and Akt signaling via PTPN13 mediated phosphorylation.
3.The lysine methyltransferase SMYD2 methylates the kinase domain of type II receptor BMPR2 and stimulates bone morphogenetic protein signaling.
Gao S;Wang Z;Wang W;Hu X;Chen P;Li J;Feng X;Wong J;Du JX J Biol Chem. 2017 Jul 28;292(30):12702-12712. doi: 10.1074/jbc.M117.776278. Epub 2017 Jun 6.
Lysine methylation of chromosomal and nuclear proteins is a well-known mechanism of epigenetic regulation, but relatively little is known about the role of this protein modification in signal transduction. Using an RNAi-based functional screening of the SMYD family of lysine methyltransferases (KMTs), we identified SMYD2 as a KMT essential for robust bone morphogenic protein (BMP)- but not TGFβ-induced target gene expression in HaCaT keratinocyte cells. A role for SMYD2 in BMP-induced gene expression was confirmed by shRNA knockdown and CRISPR/Cas9-mediated knock-out of ;SMYD2; We further demonstrate that ;SMYD2; knockdown or knock-out impairs BMP-induced phosphorylation of the signal-transducing protein SMAD1/5 and SMAD1/5 nuclear localization and interaction with SMAD4. The SMYD2 KMT activity was required to facilitate BMP-mediated signal transduction, as treatment with the SMYD2 inhibitor AZ505 suppressed BMP2-induced SMAD1/5 phosphorylation. Furthermore, we present evidence that SMYD2 likely modulates the BMP response through its function in the cytosol. We show that, although SMYD2 interacted with multiple components in the BMP pathway, it specifically methylated the kinase domain of BMP type II receptor BMPR2.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related HMTase Products

CAS 1380316-03-9 EPZ004777 hydrochloride

EPZ004777 hydrochloride
(CAS: 1380316-03-9)

EPZ004777 selectively inhibits cellular H3K79 methylation and inhibits expression of key MLL fusion target genes. Following DOT1L inhibition, EPZ004777 selectiv...

CAS 1035227-43-0 AZ505

(CAS: 1035227-43-0)

AZ505 is a potent and highly selective inhibitor of the oncogenic protein SMYD2(IC50=0.12 μM) with potential anticancer activity.

CAS 1415800-43-9 UNC1215

(CAS: 1415800-43-9)

UNC1215 is a potent, selective antagonist of L3MBTL3 with cellular activity. UNC1215 has an IC50 of 20 nM and > 100-fold selectivity over 13 HMTs and selected r...

CAS 1020399-49-8 CARM1-IN-1

(CAS: 1020399-49-8)

CARM1-IN-1 is a potent and specific CARM1(Coactivator-associated arginine methyltransferase 1) inhibitor with IC50 of 8.6 μM and shows very low activity against...

CAS 1320288-17-2 UNC0646

(CAS: 1320288-17-2)

UNC-0646 is a novel G9a inhibitor with excellent potency in a variety of cell lines and excellent separation of functional potency versus cell toxicity.

CAS 6398-98-7 Amodiaquin dihydrochloride dihydrate

Amodiaquin dihydrochloride dihydrate
(CAS: 6398-98-7)

Amodiaquine, a 4-aminoquinoquinoline compound, has is a histamine N-methyltransferase inhibitor, used as an antimalarial and anti-inflammatory agent been used a...

CAS 1821908-48-8 SGC2085

(CAS: 1821908-48-8)

SGC2085, also called as GTPL9259, is a potent and selective Coactivator Associated Arginine Methyltransferase 1 (CARM1), which has an IC50 of 50 nM for CARM1 an...

CAS 587850-67-7 C7280948

(CAS: 587850-67-7)

C7280948 is a novel PRMT1 inhibitor ( IC50=12.75 μM).

Chemical Structure

CAS 1035227-43-0 AZ505

Quick Inquiry

Verification code

Featured Items